Autoimmune disorders are often associated with low platelet count or thrombocytopenia. In
immune-induced thrombocytopenia (IIT), a common mechanism is increased platelet …

Introduction This systematic review aimed to retrieve patients diagnosed with de novo
immune thrombocytopenic purpura (ITP) after COVID‐19 immunization to determine their …

Systemic autoimmune and inflammatory diseases have a complex and only partially known
pathophysiology with various abnormalities involving all the components of the immune …

Immune thrombocytopenic purpura (ITP) is a blood disorder characterized by a low platelet
count of (less than 100× 109/L). ITP is an organ-specific autoimmune disease in which the …

Background: Immune thrombocytopenia (ITP) is characterized by primarily autoantibody-
mediated platelet destruction and impaired platelet production resulting in thrombocytopenia …

Despite the efficacy of splenectomy for chronic immune thrombocytopenia (ITP), its
considerable failure rate and its possible related complications prove the need for further …

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can occur due to maternal IgG
antibodies targeting platelet antigens, causing life-threatening bleeding in the neonate …

Immune thrombocytopenic purpura (ITP) is an acquired antibody or cell-mediated platelet
damage or decreased platelet production. Steroids, IV immunoglobulins (IVIG), and Rho-anti …

Primary immune thrombocytopenia (ITP) is an autoimmune disorder that causes low platelet
counts and subsequent bleeding risk. Although current corticosteroid-based ITP therapies …

For many decades immune thrombocytopenia (ITP) was managed using therapies which
had not undergone randomised clinical trials and included corticosteroids, immune …